Based on the relevance of high IDO1 and TDO2 expression in many tumours and their poor prognosis, and the role of many products of the KP metabolic in driving tumour development, we believe it is reasonable to explore IDO inhibitors, TDO2 inhibitors and dual IDO1/TDO2 inhibitors. The gene discussed is IDO1; the disease is neoplasm.